An anonymous reader writes: We recently read about a U.S. company that bought the rights to a drug called Daraprim and then boosted the price over 5,000%. There was widespread outrage over this blatant price gouging, most of it focused on hedge fund manager Martin Shkreli. Now, a San Diego-based drug company called Imprimis has stepped in to fill the void. They announced that they'll be supplying capsules containing the same active ingredients in Daraprim for $1 per dose. Their CEO, Mark Baum, said they'll also start making alternative versions of other generic medicines that have skyrocketed in price lately. "Imprimis, which primarily makes compounded drugs to treat cataracts and urological conditions, will work with health insurers and prescription benefit managers in each state to make its new capsules and other compounded generic medicines widely available, Baum said."